ArticleAlimentary pharmacology & therapeutics2024
A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States.
Article in Alimentary pharmacology & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Embedding metabolic dysfunction-associated steatotic liver disease fibrosis risk stratification within pharmacist-integrated diabetes comanagement in primary care.Journal of managed care & specialty pharmacy · 2026Article
- The Prevalence and Risk Factors for at-Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care.Alimentary pharmacology & therapeutics · 2026Article
- Real-world quality of life and healthcare resource utilization in patients with metabolic dysfunction-associated steatohepatitis.JHEP reports : innovation in hepatology · 2026Article
- The bidirectional relationship between diabetes mellitus and liver disease: Mechanisms, clinical implications, and management strategies.Endocrine · 2026Review
- Bidirectional relationship between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus.EXCLI journal · 2026Review
- Association of one-hour postload plasma glucose combined with metabolic dysfunction-associated steatotic liver disease and FIB-4 screening positivity with elevated LDL cholesterol and cerebrovascular stenosis.Frontiers in endocrinology · 2026Article
- The association between childhood obesity and major adverse liver outcomes in adolescence and young adulthood.JHEP reports : innovation in hepatology · 2025Article
- Weight-adjusted waist circumference index with hepatic steatosis and fibrosis in adult females: a cross-sectional, nationally representative study (NHANES 2017-2020).BMC gastroenterology · 2025Article
- Coming of age: could obesity-related metabolic complications be treated by targeting senescent cells?Frontiers in cell and developmental biology · 2025Review
- Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis.Cell reports. Medicine · 2024Article
- Increased risk of vascular complications in patients with type 2 diabetes and fatty liver disease.BMC endocrine disorders · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThere are limited data on the prevalence and treatment of at-risk metabolic dysfunction-associated steatohepatitis (MASH) among patients with type 2 diabetes (T2DM) in the United States.
aimTo estimate the prevalence of at-risk MASH in a prospectively recruited cohort of adults with T2DM using new nomenclature endorsed by multiple societies.
methodsThis prospective study enrolled adults aged ≥50 with T2DM from primary care and endocrinology clinics in southern California from 2016 to 2023. Metabolic dysfunction-associated steatotic liver disease (MASLD) was defined by an magnetic resonance imaging proton density fat fraction ≥5% and at least one metabolic risk factor without any other chronic liver disease or secondary cause for hepatic steatosis.
resultsWe included 530 adult patients with T2DM. The mean (±SD) age and body mass index (BMI) were 64.4 (±8.1) years and 31.5 (±6.1) kg/m
conclusionAmong adults aged ≥50 years with T2DM, the prevalence of MASLD, at-risk MASH and cirrhosis is high, posing a significant risk for liver-related morbidity and mortality. Approximately 14% of patients with T2DM may be candidates for pharmacologic therapies specific to MASH-related fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.